Skip to main content
Top
Published in: BMC Psychiatry 1/2010

Open Access 01-12-2010 | Research article

Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia

Authors: Haya Ascher-Svanum, Allen W Nyhuis, Douglas E Faries, Daniel E Ball, Bruce J Kinon

Published in: BMC Psychiatry | Issue 1/2010

Login to get access

Abstract

Background

Individuals with schizophrenia may have a higher risk of encounters with the criminal justice system than the general population, but there are limited data on such encounters and their attendant costs. This study assessed the prevalence of encounters with the criminal justice system, encounter types, and the estimated cost attributable to these encounters in the one-year treatment of persons with schizophrenia.

Methods

This post-hoc analysis used data from a prospective one-year cost-effectiveness study of persons treated with antipsychotics for schizophrenia and related disorders in the United States. Criminal justice system involvement was assessed using the Schizophrenia Patients Outcome Research Team (PORT) client survey and the victimization subscale of the Lehman Quality of Life Interview (QOLI). Direct cost of criminal justice system involvement was estimated using previously reported costs per type of encounter. Patients with and without involvement were compared on baseline characteristics and direct annual health care and criminal justice system-related costs.

Results

Overall, 278 (46%) of 609 participants reported at least 1 criminal justice system encounter. They were more likely to be substance users and less adherent to antipsychotics compared to participants without involvement. The 2 most prevalent types of encounters were being a victim of a crime (67%) and being on parole or probation (26%). The mean annual per-patient cost of involvement was $1,429, translating to 6% of total annual direct health care costs for those with involvement (11% when excluding crime victims).

Conclusions

Criminal justice system involvement appears to be prevalent and costly for persons treated for schizophrenia in the United States. Findings highlight the need to better understand the interface between the mental health and the criminal justice systems and the related costs, in personal, societal, and economic terms.
Literature
1.
go back to reference Morissey J, Meyer P, Cuddeback G: Extending assertive community treatment to criminal justice settings: origins, current evidence, and future directions. Community Ment Health J. 2007, 43 (5): 527-544. 10.1007/s10597-007-9092-9.CrossRef Morissey J, Meyer P, Cuddeback G: Extending assertive community treatment to criminal justice settings: origins, current evidence, and future directions. Community Ment Health J. 2007, 43 (5): 527-544. 10.1007/s10597-007-9092-9.CrossRef
3.
go back to reference McFarland BH, Faulkner LR, Bloom JD, Hallaux R, Bray JD: Chronic mental illness and the criminal justice system. Hosp Community Psychiatry. 1989, 40 (7): 718-723.PubMed McFarland BH, Faulkner LR, Bloom JD, Hallaux R, Bray JD: Chronic mental illness and the criminal justice system. Hosp Community Psychiatry. 1989, 40 (7): 718-723.PubMed
4.
go back to reference Jacobson A, Richardson B: Assault experiences of 100 psychiatric inpatients: evidence of the need for routine inquiry. Am J Psychiatry. 1987, 144 (7): 908-913.CrossRefPubMed Jacobson A, Richardson B: Assault experiences of 100 psychiatric inpatients: evidence of the need for routine inquiry. Am J Psychiatry. 1987, 144 (7): 908-913.CrossRefPubMed
5.
go back to reference McEvoy JP: The costs of schizophrenia. J Clin Psychiatry. 2007, 68 (Suppl 14): 4-7.PubMed McEvoy JP: The costs of schizophrenia. J Clin Psychiatry. 2007, 68 (Suppl 14): 4-7.PubMed
6.
7.
go back to reference Rascati KL, Johnsrud MT, Crismon ML, Lage MJ, Barber BL: Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid patients. Pharmacoeconomics. 2003, 21 (10): 683-697. 10.2165/00019053-200321100-00001.CrossRefPubMed Rascati KL, Johnsrud MT, Crismon ML, Lage MJ, Barber BL: Olanzapine versus risperidone in the treatment of schizophrenia: a comparison of costs among Texas Medicaid patients. Pharmacoeconomics. 2003, 21 (10): 683-697. 10.2165/00019053-200321100-00001.CrossRefPubMed
8.
go back to reference Byerly MJ, Weber M, Brooks D, Casey SB, Elliot S, Hawkins J: Cost evaluation of risperidone compared with olanzapine. Psychiatr Serv. 2003, 54 (5): 742-744. 10.1176/appi.ps.54.5.742.CrossRefPubMed Byerly MJ, Weber M, Brooks D, Casey SB, Elliot S, Hawkins J: Cost evaluation of risperidone compared with olanzapine. Psychiatr Serv. 2003, 54 (5): 742-744. 10.1176/appi.ps.54.5.742.CrossRefPubMed
9.
go back to reference Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA: Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. J Ment Health Policy Econ. 2008, 11 (2): 89-97.PubMed Stargardt T, Weinbrenner S, Busse R, Juckel G, Gericke CA: Effectiveness and cost of atypical versus typical antipsychotic treatment for schizophrenia in routine care. J Ment Health Policy Econ. 2008, 11 (2): 89-97.PubMed
10.
go back to reference Knapp M, Mangalore R, Simon J: The global costs of schizophrenia. Schizophr Bull. 2004, 30 (2): 279-293.CrossRefPubMed Knapp M, Mangalore R, Simon J: The global costs of schizophrenia. Schizophr Bull. 2004, 30 (2): 279-293.CrossRefPubMed
11.
go back to reference Mangalore R, Knapp M: Cost of schizophrenia in England. J Ment Health Policy Econ. 2007, 10 (1): 23-41.PubMed Mangalore R, Knapp M: Cost of schizophrenia in England. J Ment Health Policy Econ. 2007, 10 (1): 23-41.PubMed
12.
go back to reference Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J: The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005, 66 (9): 1122-1129. 10.4088/JCP.v66n0906.CrossRefPubMed Wu EQ, Birnbaum HG, Shi L, Ball DE, Kessler RC, Moulis M, Aggarwal J: The economic burden of schizophrenia in the United States in 2002. J Clin Psychiatry. 2005, 66 (9): 1122-1129. 10.4088/JCP.v66n0906.CrossRefPubMed
13.
go back to reference Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R: Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health. 2006, 9 (2): 77-89. 10.1111/j.1524-4733.2006.00083.x.CrossRefPubMed Tunis SL, Faries DE, Nyhuis AW, Kinon BJ, Ascher-Svanum H, Aquila R: Cost-effectiveness of olanzapine as first-line treatment for schizophrenia: results from a randomized, open-label, 1-year trial. Value Health. 2006, 9 (2): 77-89. 10.1111/j.1524-4733.2006.00083.x.CrossRefPubMed
14.
go back to reference Overall JE, Gorham DR: The brief psychiatric rating scale. Psychol Rep. 1962, 10: 799-812.CrossRef Overall JE, Gorham DR: The brief psychiatric rating scale. Psychol Rep. 1962, 10: 799-812.CrossRef
15.
go back to reference Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987, 13 (2): 261-276.CrossRefPubMed Kay SR, Fiszbein A, Opler LA: The positive and negative syndrome scale (PANSS) for schizophrenia. Schizophr Bull. 1987, 13 (2): 261-276.CrossRefPubMed
16.
go back to reference Ware JE, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992, 30 (6): 473-483. 10.1097/00005650-199206000-00002.CrossRefPubMed Ware JE, Sherbourne CD: The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992, 30 (6): 473-483. 10.1097/00005650-199206000-00002.CrossRefPubMed
17.
go back to reference Valenstein M, Copeland LA, Blow FC, McCarthy JF, Zeber JE, Gillon L, Bingham CR, Stavenger T: Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care. 2002, 40 (8): 630-639. 10.1097/00005650-200208000-00002.CrossRefPubMed Valenstein M, Copeland LA, Blow FC, McCarthy JF, Zeber JE, Gillon L, Bingham CR, Stavenger T: Pharmacy data identify poorly adherent patients with schizophrenia at increased risk for admission. Med Care. 2002, 40 (8): 630-639. 10.1097/00005650-200208000-00002.CrossRefPubMed
18.
go back to reference Lehman AF, Steinwachs DM: Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr Bull. 1998, 24 (1): 11-20.CrossRefPubMed Lehman AF, Steinwachs DM: Patterns of usual care for schizophrenia: initial results from the Schizophrenia Patient Outcomes Research Team (PORT) Client Survey. Schizophr Bull. 1998, 24 (1): 11-20.CrossRefPubMed
19.
go back to reference Lehman AF: A quality of life interview for the chronically mentally ill. Eval Program Plann. 1988, 11 (1): 51-62. 10.1016/0149-7189(88)90033-X.CrossRef Lehman AF: A quality of life interview for the chronically mentally ill. Eval Program Plann. 1988, 11 (1): 51-62. 10.1016/0149-7189(88)90033-X.CrossRef
20.
go back to reference Clark RE, Ricketts SK, McHugo GJ: Legal system involvement and costs for persons in treatment for severe mental illness and substance use disorders. Psychiatr Serv. 1999, 50 (5): 641-647.CrossRefPubMed Clark RE, Ricketts SK, McHugo GJ: Legal system involvement and costs for persons in treatment for severe mental illness and substance use disorders. Psychiatr Serv. 1999, 50 (5): 641-647.CrossRefPubMed
22.
go back to reference Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW: Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006, 67 (3): 453-460. 10.4088/JCP.v67n0317.CrossRefPubMed Ascher-Svanum H, Faries DE, Zhu B, Ernst FR, Swartz MS, Swanson JW: Medication adherence and long-term functional outcomes in the treatment of schizophrenia in usual care. J Clin Psychiatry. 2006, 67 (3): 453-460. 10.4088/JCP.v67n0317.CrossRefPubMed
23.
go back to reference Swanson JW, Swartz MS, Van Dorn RA, Volavka J, Monahan J, Stroup TS, McEvoy JP, Wagner HR, Elbogen EB, Lieberman JA, CATIE investigators: Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry. 2008, 193 (1): 37-43. 10.1192/bjp.bp.107.042630.CrossRefPubMedPubMedCentral Swanson JW, Swartz MS, Van Dorn RA, Volavka J, Monahan J, Stroup TS, McEvoy JP, Wagner HR, Elbogen EB, Lieberman JA, CATIE investigators: Comparison of antipsychotic medication effects on reducing violence in people with schizophrenia. Br J Psychiatry. 2008, 193 (1): 37-43. 10.1192/bjp.bp.107.042630.CrossRefPubMedPubMedCentral
24.
go back to reference Swanson JW, Swartz MS, Elbogen EB, Van Dorn RA: Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. J Clin Psychiatry. 2004, 65 (12): 1666-1673.CrossRefPubMed Swanson JW, Swartz MS, Elbogen EB, Van Dorn RA: Reducing violence risk in persons with schizophrenia: olanzapine versus risperidone. J Clin Psychiatry. 2004, 65 (12): 1666-1673.CrossRefPubMed
25.
go back to reference Swanson JW, Swartz MS, Elbogen EB: Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophr Bull. 2004, 30 (1): 3-20.CrossRefPubMed Swanson JW, Swartz MS, Elbogen EB: Effectiveness of atypical antipsychotic medications in reducing violent behavior among persons with schizophrenia in community-based treatment. Schizophr Bull. 2004, 30 (1): 3-20.CrossRefPubMed
26.
go back to reference Theriot MT, Segal SP: Involvement with the criminal justice system among new clients at outpatient mental health agencies. Psychiatr Serv. 2005, 56 (2): 179-185. 10.1176/appi.ps.56.2.179.CrossRefPubMed Theriot MT, Segal SP: Involvement with the criminal justice system among new clients at outpatient mental health agencies. Psychiatr Serv. 2005, 56 (2): 179-185. 10.1176/appi.ps.56.2.179.CrossRefPubMed
27.
go back to reference Swartz MS, Swanson JW, Hiday VA, Borum R, Wagner R, Burns BJ: Taking the wrong drugs: the role of substance abuse and medication noncompliance in violence among severely mentally ill individuals. Soc Psychiatry Psychiatr Epidemiol. 1998, 33 (Suppl 1): S75-S80. 10.1007/s001270050213.CrossRefPubMed Swartz MS, Swanson JW, Hiday VA, Borum R, Wagner R, Burns BJ: Taking the wrong drugs: the role of substance abuse and medication noncompliance in violence among severely mentally ill individuals. Soc Psychiatry Psychiatr Epidemiol. 1998, 33 (Suppl 1): S75-S80. 10.1007/s001270050213.CrossRefPubMed
28.
go back to reference Baillargeon J, Binswanger IA, Penn JV, Williams BA, Murray OJ: Psychiatric disorders and repeat incarcerations: the revolving prison door. Am J Psychiatry. 2009, 166 (1): 103-109. 10.1176/appi.ajp.2008.08030416.CrossRefPubMed Baillargeon J, Binswanger IA, Penn JV, Williams BA, Murray OJ: Psychiatric disorders and repeat incarcerations: the revolving prison door. Am J Psychiatry. 2009, 166 (1): 103-109. 10.1176/appi.ajp.2008.08030416.CrossRefPubMed
29.
go back to reference Swanson JW, Swartz MS, Van Dorn RA, Elbogen EB, Wagner HR, Rosenheck RA, Stroup TS, McEvoy JP, Lieberman JA: A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry. 2006, 63 (5): 490-499. 10.1001/archpsyc.63.5.490.CrossRefPubMed Swanson JW, Swartz MS, Van Dorn RA, Elbogen EB, Wagner HR, Rosenheck RA, Stroup TS, McEvoy JP, Lieberman JA: A national study of violent behavior in persons with schizophrenia. Arch Gen Psychiatry. 2006, 63 (5): 490-499. 10.1001/archpsyc.63.5.490.CrossRefPubMed
30.
go back to reference Hiday VA, Swartz MS, Swanson JW, Borum R, Wagner HR: Criminal victimization of persons with severe mental illness. Psychiatr Serv. 1999, 50: 62-68.CrossRefPubMed Hiday VA, Swartz MS, Swanson JW, Borum R, Wagner HR: Criminal victimization of persons with severe mental illness. Psychiatr Serv. 1999, 50: 62-68.CrossRefPubMed
31.
go back to reference Lehman AF, Linn LS: Crimes against discharged mental patients in board-and-care homes. Am J Psychiatry. 1984, 141: 271-274.CrossRefPubMed Lehman AF, Linn LS: Crimes against discharged mental patients in board-and-care homes. Am J Psychiatry. 1984, 141: 271-274.CrossRefPubMed
Metadata
Title
Involvement in the US criminal justice system and cost implications for persons treated for schizophrenia
Authors
Haya Ascher-Svanum
Allen W Nyhuis
Douglas E Faries
Daniel E Ball
Bruce J Kinon
Publication date
01-12-2010
Publisher
BioMed Central
Published in
BMC Psychiatry / Issue 1/2010
Electronic ISSN: 1471-244X
DOI
https://doi.org/10.1186/1471-244X-10-11

Other articles of this Issue 1/2010

BMC Psychiatry 1/2010 Go to the issue